Aurora Cannabis Expands Medical Cannabis Pastille Offerings in Australia

$ACB
Medicinal Chemicals and Botanical Products
Health Care
Get the next $ACB alert in real time by email

Canada's Leading Medical Cannabis Company Broadens Innovative Product Portfolio to Growing Market in Australia

EDMONTON, AB, Feb. 20, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, has announced today the company's extended pastille offerings in Australia. This expansion marks another meaningful step in Aurora's deep commitment to offering patients a diverse range of high-quality, premium medical cannabis products to meet their various needs and interests.

"Expanding our portfolio of medical cannabis pastilles in Australia demonstrates our understanding of market demand and is another example of our ability to bring high quality product to this key market as patient interest increases," said Andre Jerome, Executive Vice President of Global Business Development at Aurora. "In this rapidly expanding market, we're leveraging our unique capabilities, including global manufacturing and excellence in navigating regulatory frameworks that define Aurora's leadership."

Medical cannabis pastilles offer several key benefits, including easy oral intake. The prolonged effects provide long-lasting and extended relief after digestion. Pastilles also come in an accessible format that is discrete, portable, and convenient.

The pastilles that are now available in Australia include:

  • Aurora Pastilles - 10mg THC Pomegranate Berry (30 pack)
  • Aurora Pastilles - 10:10 Balanced Pineapple (30 pack)
  • Aurora Pastilles - 25mg CBD Acai Berry (30 pack)

Aurora maintains its position as the largest global medical cannabis company operating in nationally legal markets. The company has a robust innovation pipeline planned for global introduction over the course of the coming months, bringing variety and new options to patients.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at   www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information:    

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's expanded pastilles offerings in the Australian market, including the associated benefits to the Company, as well as the benefits to the pastille format for patients, and statements regarding expectations for the continued rapid expansion of the Australian market, the Company's upcoming innovation pipeline, and position as the largest medical global cannabis company operating in nationally legal markets.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-expands-medical-cannabis-pastille-offerings-in-australia-302381814.html

SOURCE Aurora Cannabis Inc.

Get the next $ACB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ACB

DatePrice TargetRatingAnalyst
12/11/2024Buy
TD Cowen
2/9/2024Hold → Buy
Canaccord Genuity
9/21/2022Sell → Hold
Canaccord Genuity
6/24/2022Neutral → Overweight
Cantor Fitzgerald
6/6/2022Sell → Hold
Stifel
11/10/2021$9.60 → $10.75Neutral
Cantor Fitzgerald
10/28/2021$9.50 → $9.60Neutral
Cantor Fitzgerald
10/5/2021$8.30 → $9.50Neutral
Cantor Fitzgerald
More analyst ratings

$ACB
Press Releases

Fastest customizable press release news feed in the world

See more
  • Aurora Cannabis Recognized for Executive Gender Diversity by The Globe and Mail

    Canada's Largest Medical Cannabis Company is an Honouree in The Globe and Mail's 2025 Report on Business Magazine's sixth annual Women Lead Here List EDMONTON, AB, March 31, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, has been named an honouree on the Globe & Mail's 2025 Report on Business, Women Lead Here list. This annual editorial benchmark recognizes the top publicly traded Canadian companies with the highest gender diversity at the executive level. "As a company with a leading purpose of bein

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
  • Aurora Cannabis to Speak at the Global Cannabis Regulatory Summit

    NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company to Participate as an Industry Leader in the Inaugural Regulatory Event in Washington, D.C. EDMONTON, AB, March 25, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is pleased to be attending, sponsoring and speaking at the 2025 Global Cannabis Regulatory Summit (GCRS), held within the U.S. Capitol Complex in Washington, D.C. on March 26-27, 2025. "The opportunity to speak on this global stage, underscores our position as industry leaders and d

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
  • Aurora Cannabis Announces Breakthrough Discovery of Powdery Mildew Resistant Cultivars

    NASDAQ | TSX: ACB Groundbreaking research at Aurora Coast, Aurora's world-class research and development facility, sets new standard in cannabis science EDMONTON, AB, March 20, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is pleased to announce the Company's discovery of a novel source of genetic resistance against powdery mildew, PM2, that provides strong protection against this pathogen in cannabis sativa. The development of this proprietary genetic marker technology, which is now in use in Aurora's breeding program, is set to produce powdery mildew resistant cultivars that will be explored for commercial launc

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

$ACB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ACB
SEC Filings

See more

$ACB
Leadership Updates

Live Leadership Updates

See more
  • Aurora CEO Miguel Martin takes on additional role as Executive Chairman of Board of Directors

    NASDAQ | TSX: ACB Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB, Sept. 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director. Both appointments follow unanimous votes by Aurora's Board and are effective immediately. Mr. Martin has served as Chief Executiv

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
  • Aurora Cannabis Announces Results of 2024 Annual General and Special Meeting

    NASDAQ | TSX: ACB EDMONTON, AB, Aug. 12, 2024 /PRNewswire/ -  Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held Friday August 9, 2024 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and by proxy at the Meeting was 14,855,306, representing 27.23% of Aurora's issued and outstanding common shares as of the record date. All of

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
  • Aurora Cannabis Announces Appointment of New Director

     NASDAQ | TSX: ACB  Newly created directorship to be filled by Rajesh Uttamchandani EDMONTON, AB, May 15, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today the appointment of Rajesh Uttamchandani to the Company's Board of Directors (the "Board"), effective today. Mr. Uttamchandani joins the Board with notable expertise in strategy development, innovation, human capital and governance. His impressive career is characterized by executive level roles with leadin

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

$ACB
Financials

Live finance-specific insights

See more
  • Aurora Cannabis Announces Fiscal 2025 Third Quarter Results

    NASDAQ | TSX: ACB Reports Total Net Revenue1 of $88.2 Million, up 37% YoY, Including Record Net Revenue1 of $68.1 Million in Global Medical Cannabis, up 51% YoYGenerates Record Net Income of $31.2 Million, up 282% YoY, and Record Adjusted EBITDA1 of $23.1 Million, up 316% YoYAchieves Target of Positive Free Cash Flow1 in Q3, Generating $27.4 Million of Free Cash Flow1Maintains Strong Balance Sheet with $180 Million of Cash and Debt-Free Cannabis Business2EDMONTON, AB, Feb. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third qu

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
  • Aurora Cannabis to Host Third Quarter 2025 Investor Conference Call

    NASDAQ | TSX: ACB EDMONTON, AB, Jan. 22, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its third quarter 2025 on Wednesday, February 5, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the third quarter 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, February 5, 2025 TIME: 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time WEBCAST: Click Here Miguel Martin, Executive Chairman and Chief Executive Officer,

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
  • Aurora Cannabis Announces Fiscal 2025 Second Quarter Results

    NASDAQ | TSX: ACB Record Adjusted EBITDA1 of $10.1 Million, a YoY increase of 210%Quarterly Net Revenue1 up 29% YoY to $81.1 Million, with 41% growth in Global Medical CannabisRe-Affirms Target of Positive Free Cash Flow1 in the Quarter Ending December 31, 2024Maintains Strong Balance Sheet with ~$152 Million of Cash and a Debt-Free Cannabis Business2EDMONTON, AB, Nov. 6, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter fiscal 2025.

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

$ACB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more